Abstract
Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Current Diabetes Reviews
Title:The Complex Inter-Relationship Between Diabetes and Schizophrenia
Volume: 13 Issue: 3
Author(s): Jeffrey Rado*
Affiliation:
- Department of Psychiatry and General Internal Medicine, Northwestern University, Chicago, IL,United States
Keywords: Antipsychotics, diabetes mellitus, metabolic syndrome, obesity, schizophrenia.
Abstract: Schizophrenia is a chronic and debilitating brain disorder. It is associated with increased mortality, primarily due to elevated cardio-metabolic risk. Affected patients have higher rates of obesity, metabolic syndrome and diabetes [1]. Intrinsic factors contributing to this increased risk include a shared underlying pathophysiology between schizophrenia and diabetes mellitus involving stress, inflammation and genetics. Extrinsic contributing factors include diet, lifestyle, health care access, low socioeconomic status and overburden of traditional diabetes risk factors. Antipsychotics are associated with an increased risk of obesity, metabolic syndrome and diabetes mellitus [1]. Appetite-regulating hormones, pharmacodynamics and alterations in glucose metabolism may underlie the negative effect of these medications. Reduction in diabetes risk is achieved by mitigating traditional risk factors. Non-pharmacologic and pharmacologic approaches to cardio-metabolic risk reduction may be helpful in these patients.
Export Options
About this article
Cite this article as:
Rado Jeffrey*, The Complex Inter-Relationship Between Diabetes and Schizophrenia, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666161220144740
DOI https://dx.doi.org/10.2174/1573399812666161220144740 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Nutrition & Food Science C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design Antioxidant and Antinociceptive Activities of Methanol Extract of Muehlenbeckia sagittifolia
Current Traditional Medicine Cytokine Gene Variants as Predictors of Type 2 Diabetes Mellitus
Current Diabetes Reviews GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Association Between the Chronic Use of Non-Steroidal Anti- Inflammatory Drugs and Oxidative and Inflammatory Markers in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Scaffold Hopping for Identification of Novel PKCβII Inhibitors Based on Ligand and Structural Approaches, Virtual Screening and Molecular Dynamics Study
Combinatorial Chemistry & High Throughput Screening Common Structural Stability Properties of 4-Helical Bundle Cytokines: Possible Physiological and Pharmaceutical Consequences
Current Pharmaceutical Design Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Therapeutic Potential of Coagonists of Glucagon and GLP-1
Cardiovascular & Hematological Agents in Medicinal Chemistry Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties
Current Medicinal Chemistry First Autochthonous case of Emerged Zoonotic Cutaneous Leishmaniasis in Mazandaran Province, Northern Iran: kDNA-PCR Evidence Base
Infectious Disorders - Drug Targets Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Growth Hormone/Insulin-Like Growth Factor-I Axis and Insulin in Alzheimers Disease and Its Possible Treatment Usefulness
Central Nervous System Agents in Medicinal Chemistry Autoimmunity in Alzheimers Disease as Evidenced by Plasma Immunoreactivity Against RAGE and Aβ42: Complication of Diabetes
Current Alzheimer Research Editorial [Innovative Therapeutic Approaches for the Treatment of Pediatric Autoimmune and Inflammatory Diseases Executive (Guest Editor: Giorgio Zauli)]
Current Pharmaceutical Design Editorial (Thematic Issue: Natural Polyphenols and Diabetes: Understanding their Mechanism of Action)
Current Medicinal Chemistry Investigating the Relationship the Severity of Coronary Artery Disease with Serum Levels of Vitamin D in Men after Eliminating the Effect of Diet
Current Nutrition & Food Science Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery